Aclaris Therapeutics, Inc.
corporate_fare Company Profile
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ACRS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Aclaris Therapeutics Reports Q4/FY2025 Results, Extends Cash Runway to H2 2028, Advances Multiple Pipeline Programs
- Aclaris Therapeutics Unveils Strong Clinical Pipeline Progress and Extended Cash Runway
- Aclaris Therapeutics Reports Positive Phase 1a Results for ATI-052, Advancing to Phase 1b/2b Trials
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$7.83M
Net Income
-$64.92M
Diluted EPS
-$0.53
Op. Cash Flow
-$47.11M
Free Cash Flow
-$47.22M
Gross Profit
$5.74M
Operating Income
-$76.38M
Cash & Equivalents
$19.96M
Debt / Equity
0.00×
Net Margin
-8.30×
Shares Outstanding
120.5M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020540
show_chartPrice Chart
Loading chart...
feed ACRS - Filings & News (Page 2)
ACRS
Feb 26, 2026, 7:15 AM EST
Price at Filing:
$3.23
Real-time Price:
$3.44
Change:
+$0.210 (+7%)
Market Cap:
$545.626M
ACRS
Jan 12, 2026, 7:00 AM EST
Price at Filing:
$2.64
Real-time Price:
$3.44
Change:
+$0.800 (+30%)
Market Cap:
$545.626M
ACRS
Jan 06, 2026, 7:16 AM EST
Price at Filing:
$2.78
Real-time Price:
$3.44
Change:
+$0.660 (+24%)
Market Cap:
$545.626M